Top 10 Companies in the (R)-N-Fmoc-3-Bromophenylalanine (CAS 220497-81-4) Market (2026): Market Leaders Powering Global Peptide Innovation

MARKET INSIGHTS

Global (R)-N-Fmoc-3-Bromophenylalanine (CAS 220497-81-4) market size was valued at USD 38.6 million in 2025. The market is projected to grow from USD 41.2 million in 2026 to USD 74.8 million by 2034, exhibiting a CAGR of 6.9% during the forecast period.

(R)-N-Fmoc-3-Bromophenylalanine (CAS 220497-81-4) is a protected, non-natural amino acid derivative widely utilized in solid-phase peptide synthesis (SPPS). The Fmoc (9-fluorenylmethoxycarbonyl) protecting group on the nitrogen enables controlled, stepwise peptide chain assembly, while the bromine substituent at the meta position of the phenylalanine side chain offers a versatile handle for further chemical functionalization, including cross-coupling reactions such as Suzuki and Heck reactions.

The market is experiencing steady growth driven by rising demand for peptide-based therapeutics, increasing investment in drug discovery research, and the expanding use of unnatural amino acids in the development of bioactive compounds. Furthermore, the compound’s utility in producing structurally complex peptides for pharmaceutical and biotechnology applications continues to broaden its relevance. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), Bachem AG, Iris Biotech GmbH, and Combi‑Blocks, Inc., all of which maintain active portfolios of Fmoc‑protected amino acid building blocks.

(R)-N-Fmoc-3-Bromophenylalanine (CAS 220497-81-4) Market – View in Detailed Research Report

Top 10 Companies in the (R)-N-Fmoc-3-Bromophenylalanine (CAS 220497-81-4) Market

1️⃣ Bachem AG

Headquarters: Brünigen, Switzerland
Key Offering: High‑purity Fmoc‑protected amino acids, custom synthesis, and peptide manufacturing services

Bachem AG is a global leader in peptide and amino acid chemistry, providing a comprehensive range of Fmoc‑protected building blocks for pharmaceutical and academic research. Their integrated manufacturing facilities across Europe and the United States enable rapid scale‑up and stringent quality control, ensuring consistent stereochemical integrity and minimal impurities.

Growth Initiatives:

• Expansion of contract development and manufacturing organization (CDMO) services in North America and Asia‑Pacific.
• Investment in automated SPPS platforms to reduce lead times.
• Partnerships with biotech firms for bespoke peptide libraries.

2️⃣ Merck KGaA (Sigma‑Aldrich)

Headquarters: Darmstadt, Germany
Key Offering: Extensive portfolio of Fmoc‑protected unnatural amino acids, analytical services, and GMP‑grade production

Through its Sigma‑Aldrich division, Merck KGaA delivers high‑purity reagents for drug discovery and process development. Their global distribution network and robust quality management system support the needs of pharmaceutical companies and research institutions worldwide.

Growth Initiatives:

• Strategic acquisitions of specialty chemical manufacturers to broaden product offerings.
• Development of greener synthesis routes to reduce solvent usage.
• Expansion of custom synthesis capabilities for rare‑earth amino acids.

3️⃣ Sigma‑Aldrich Corporation

Headquarters: St. Louis, USA
Key Offering: Comprehensive catalog of Fmoc‑protected amino acids and specialty reagents

Sigma‑Aldrich remains a cornerstone supplier for the life sciences, offering a vast array of Fmoc‑protected building blocks that meet cGMP and research‑grade specifications. Their strong R&D pipeline ensures continuous innovation in chiral synthesis.

Growth Initiatives:

• Launch of rapid synthesis services for custom peptides.
• Investment in AI‑driven synthesis optimization.
• Expansion of educational resources for peptide chemistry.

4️⃣ GL Biochem (Shanghai) Ltd.

Headquarters: Shanghai, China
Key Offering: Catalog and custom Fmoc‑protected amino acids, large‑scale production

GL Biochem has rapidly scaled its production capacity to meet the growing demand from China’s booming biopharma sector. Their modern facilities in Shanghai provide cost‑effective, high‑quality reagents for both domestic and international customers.

Growth Initiatives:

• Strategic partnerships with Chinese CDMOs to capture market share.
• Development of eco‑friendly synthesis processes.
• Expansion of product portfolio to include novel halogenated amino acids.

5️⃣ Iris Biotech GmbH

Headquarters: Hamburg, Germany
Key Offering: Specialized phenylalanine analogs, custom synthesis, and chiral resolution services

Iris Biotech focuses on delivering high‑purity, enantiomerically pure phenylalanine derivatives for drug discovery and peptide engineering. Their expertise in chiral resolution ensures superior stereochemical fidelity.

Growth Initiatives:

• Collaboration with academic institutions for novel peptide design.
• Expansion of custom synthesis services for rare‑mode amino acids.
• Implementation of continuous‑flow synthesis technology.

6️⃣ Chem‑Impex International Inc.

Headquarters: San Diego, USA
Key Offering: High‑purity research‑grade Fmoc‑protected amino acids, rapid custom synthesis

Chem‑Impex specializes in providing research‑grade reagents for academic and biotech labs, emphasizing fast turnaround and stringent purity controls.

Growth Initiatives:

• Development of on‑demand synthesis platforms.
• Expansion of product lines to include rare‑mode chiral amino acids.
• Partnerships with CROs for rapid peptide screening.

7️⃣ AnaSpec, Inc.

Headquarters: North Carolina, USA
Key Offering: Custom synthesis of specialty reagents and intermediates for peptide chemistry

AnaSpec offers tailored solutions for researchers needing niche building blocks, leveraging its in‑house synthesis expertise.

Growth Initiatives:

• Investment in modular synthesis platforms.
• Expansion of analytical services for purity verification.
• Strategic alliances with academic research centers.

8️⃣ CPC Scientific, Inc.

Headquarters: San Diego, USA
Key Offering: High‑purity Fmoc‑protected amino acids, custom synthesis, and process development

CPC Scientific delivers high‑quality reagents for pharmaceutical development, with a strong focus on GMP compliance and scalable production.

Growth Initiatives:

• Expansion of CDMO services in the Asia‑Pacific region.
• Investment in biocatalytic synthesis for greener processes.
• Partnerships with biotech startups for rapid prototyping.

9️⃣ Peptide Institute Inc.

Headquarters: Tokyo, Japan
Key Offering: Custom peptide synthesis, analytical services, and peptide technology development

Peptide Institute provides end‑to‑end peptide solutions, from synthesis to characterization, supporting both pharmaceutical and academic projects.

Growth Initiatives:

• Expansion of automated SPPS platforms.
• Development of novel peptide conjugation chemistries.
• Strategic collaborations with global pharma companies.

🔟 Synthonix Inc.

Headquarters: Boston, USA
Key Offering: Specialty synthetic chemistry services, custom synthesis of Fmoc‑protected amino acids

Synthonix offers bespoke synthesis services for complex building blocks, including halogenated amino acids, with a focus on speed and quality.

Growth Initiatives:

• Investment in continuous‑flow synthesis technologies.
• Expansion of CDMO capabilities in the European market.
• Partnerships with academic institutions for novel methodology development.

Download FREE Sample Report

Get Full Report

Outlook

Over the next decade, the (R)-N‑Fmoc‑3‑Bromophenylalanine market is poised to expand, driven by the increasing pipeline of peptide therapeutics and the growing demand for advanced chemical building blocks in drug discovery. The shift toward targeted therapies, biologics, and stapled peptides will continue to elevate the need for high‑purity, enantiomerically pure reagents, sustaining market growth and encouraging further investment in synthesis technologies and supply chain resilience.

Future Trends

Key future trends include:

• Accelerated adoption of automated SPPS platforms and AI‑guided synthesis planning.
• Expansion of green chemistry initiatives, reducing solvent footprints and improving sustainability.
• Growth of click chemistry and bioorthogonal ligation strategies that leverage the bromine handle for site‑specific modifications.
• Increasing collaboration between CDMOs and academic research centers to accelerate discovery of novel peptide therapeutics.
• Emerging markets in Asia‑Pacific and Latin America driving demand for cost‑effective, high‑quality reagents.